Elizabeth Plimack, MD | Authors

Elizabeth Plimack, MD, MS, Talks Risk Categories in KEYNOTE-426 Trial on Advanced RCC

June 14, 2020

Elizabeth Plimack, MD, MS, discussed the analysis of risk categories for patients included in the KEYNOTYE-426 trial investigating axitinib and pembrolizumab over sunitinib for patients with advanced renal cell carcinoma.

Systemic Therapy for Advanced Bladder Cancer Evolves

April 11, 2018

Dr. Elizabeth Plimack discusses her 2018 AACR meeting presentation on recent advances in systemic therapy for bladder cancer.